Raymond Wu's questions to Eledon Pharmaceuticals (ELDN) leadership • Q1 2023
Question
Raymond Wu, on behalf of Matt Kaplan at Ladenburg Thalmann, asked about the response from doctors and patients to the initial renal transplantation data and whether it is building awareness for the Phase 2 trial. He also questioned how the magnitude of eGFR benefit in the BESTOW trial might influence the future clinical and regulatory path.
Answer
President and Chief Scientific Officer Steve Perrin described the physician receptivity as "absolutely amazing," noting excitement in the field to reengage the CD40 ligand pathway. CEO David-Alexandre Gros explained that the BESTOW trial is a superiority study, and even a small, statistically significant delta in eGFR would be clinically meaningful, as lower eGFR is exponentially correlated with increased hospitalization and graft failure risk. Perrin added that even small eGFR differences can significantly impact long-term graft survival.